Table 4: Comparison of clinical features and Hcy levels in active/inactive NMO patients with and without relapse in follow-up
|
NMO in active stage |
NMO in inactive stage |
P1 |
P2 |
Relapse |
No relapse |
Relapse |
No relapse |
Gender, F:M |
6:1 |
19:5 |
7:1 |
22:5 |
|
|
Age, years |
43.1 ± 12.0 |
47.0 ± 14.3 |
47.4 ± 13.1 |
41.1 ± 16.2 |
0.527 |
0.327 |
Disease duration, months |
69.6 ± 84.6 |
44.4 ± 55.9 |
59.1 ± 35.1 |
45.0 ± 50.2 |
0.359 |
0.465 |
Follow-up, months |
25.9 ± 11.6 |
23.0 ± 19.6 |
22.0 ± 25.6 |
17.8 ± 18.3 |
0.718 |
0.607 |
EDSS |
2.8 ± 0.9 |
4.4 ± 2.4 |
4.0 ± 1.5 |
3.2 ± 2.3 |
0.093 |
0.368 |
Hcy (µmol/L) |
11.0 ± 4.1 |
9.0 ± 3.2 |
11.9 ± 3.7 |
9.2 ± 3.0 |
0.181 |
0.045 |
Abbreviations: Hcy: Homocysteine; NMO: Neuromyelitis Optica; F: Female; M: Male; EDSS: Expanded Disability Status Scale; P1: NMO in active stage with relapse in follow-up vs NMO in active stage without relapse in follow-up; P2: NMO in inactive stage with relapse in follow-up vs NMO in inactive stage without relapse in follow-up.